12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

INNO-206: Phase IIb started

CytRx began an open-label, international Phase IIb trial to compare 350 mg/m 2 IV INNO-206 given once each 21-day cycle for up to 8...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >